Lacosamide Zentiva

Lacosamide, the active ingredient in Lacosamide Zentiva, is a sodium channel blocker presented as an oral dosage form for oral use. It is employed as an adjunctive therapy to control partial‑onset seizures in patients who require additional seizure management beyond their current regimen.

GNH USA supplies Lacosamide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that targets neuronal hyperexcitability associated with seizure disorders.

- Partial‑onset seizures: provides adjunctive seizure control when added to existing antiepileptic therapy.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Cardiac arrhythmia (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal ideation or behavior

Before initiating therapy, clinicians should consider several safety factors.

- Renal impairment: adjust dose as needed based on renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy: prescribe only if potential benefit justifies potential risk to the fetus. - Concomitant CNS depressants: monitor for additive sedation or respiratory depression. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide effectiveness.

Moderate Interactions (Monitor Closely): - Other antiepileptics: may enhance central nervous system depression. - Cardiac drugs affecting PR interval (e.g., beta‑blockers): require ECG monitoring. - Alcohol: may exacerbate dizziness and sedation.